Table of Contents Table of Contents
Previous Page  775 / 812 Next Page
Information
Show Menu
Previous Page 775 / 812 Next Page
Page Background

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805

S771

– the degree of antipsychotic politherapy prior to admission for the

entire sample decreased at discharge;

– at discharge, there is a difference between SDMand TaU. Antipsy-

chotic polytherapy in SDM decreases in a higher level.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2308

EV1324

The utility of omega-3 fatty acids in

depression

M.A. Quintanilla

, A. S

alas , S. Pedrosa , L. Bosqued , C. Perez ,

B. Villagrasa , B. Aguado , P. Gracia

Lozano Blesa Hospital, Psychiatry, Zaragoza, Spain

Corresponding author.

Introduction

Recent studies have reported therapeutic benefit

from the use of omega-3 fatty acids (EPA and DHA) as adjunctive

treatment of depression.

Objectives

The goal of this work is to assess the effectiveness

and tolerability of dietary supplementation with omega-3 in the

treatment of depressed patients.

Method

Prospective, descriptive, observational study in a general

psychiatry outpatient clinic. Consecutive inclusion of depressed

patients started on dietary supplementationwith omega-3 because

of partial response to antidepressants and/or intolerance to high

doses or combination of antidepressant drugs between January

and May 2015. Sociodemographic variables, clinical data and

information about tolerability were recorded. Clinical response to

treatment over time was assessed at 4–6 months follow up using

the 5-item CGI (Clinical Global Impression) scale.

Results

We included 30 depressed patients started on omega-

3. None of them reported side effects. Seventy-three percent of

patients reported clinical improvement (40% much improvement,

33% some improvement). None of them got worse. We did not find

association between clinical response and age, sex, type of depres-

sion nor duration of illness.

Conclusion

Despite the limitations of this study, our work sup-

port previous positive results on the use of omega-3 fatty acids

(EPA and DHA) as adjunctive treatment of depression. Giving the

safety of its use, clinicians might recommend omega-3 as adjunc-

tive treatment of depression in cases with a partial response to

antidepressants.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2309

EV1325

Antipsychotic injectable extended

release: A case report

M.D.L.C. Ramirez Dominguez

, L. Hernandez Gonzalez ,

I. Prieto Sánchez , A. Rodriguez Martinez , S. Fernandez Leon

Complejo Hospitalario de Huelva, Psiquiatria, Huelva, Spain

Corresponding author.

Objective

To demonstrate the therapeutic efficacy of aripiprazole

LP by a case of difficult clinical management and that we often find

in our daily practice.

Methods

Description of a clinical case of a 21-year-old man,

recently diagnosed with paranoid schizophrenia with no aware-

ness of disease neither treatment adherence and harmful use of THC

and cocaine that are identified as precipitating factors for multiple

hospital admissions.

Results

Injectable medication with objective clinical improve-

ment is significant, cessation of readmissions, achieving improve-

ment in all parameters measured functionality and proper

adherence to treatment as well as outpatient mental health of both

devices as of drug dependence.

Conclusion

Psychiatry is facing the great challenge of modifying

the natural history to the deterioration of schizophrenia, a disease

considered one of the leading causes of years lived with disability.

The objectives medium and long-term treatment of this disease

are centered on the delay-avoidance disability and improving the

functioning and quality of life of people with this disease.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2310

EV1326

Adherence to treatment and number

of relapses in patients treated with

atypical antipsychotic prolonged

release

M.D.L.C. Ramirez Dominguez

, I. Prieto Sánchez , M. Nu˜nez Caro ,

N. Garrido Torres , A.S. Biedma Martn

Complejo Hospitalario de Huelva, Psiquiatria, Huelva, Spain

Corresponding author.

Introduction

The extended release injectable offers a good alter-

native for those patients with no or poor adherence to treatment.

Numerous studies indicate that decrease the number of relapses

in such individuals. Our aim is to check whether a group of our

patients diagnosed with dual pathology coincide with these data.

Methods

We followed a group of 5 patients diagnosed with para-

noid schizophrenia or delusional disorder with drug consumption

in the last year. We measured the number of relapses, understood

as the number of visits to emergency and outpatient devicesMental

Health Hospitals and hospitalizations six months before the start

of treatment with aripiprazole injectable extended release and six

months after.

Results

The preliminary results point to a significant reduction

in the number of emergency room visits and hospitalizations after

starting sustained release injectable treatment.

Conclusions

Our preliminary results are consistent with the lit-

erature, we found also reduced consumption of toxic and better

adherence to drug addiction devices. The new antipsychotics

extended release is a good alternative for patients with dual diag-

nosis.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2311

EV1327

Electroconvulsive therapy: Brief

versus ultrabrief pulse right unilateral

electroconvulsive therapy

M.R. Raposo

1 ,

, M.L. Medina

2

, A.L. González

1

, I. Martínez

3

,

A. Gil

4

, A. Belmar

5

, M.D. Piqueras

6

, J.B. Murcia

7

, V. Ivanov

7

,

P. Manzur

7

, A. Busaileh

8

1

Servicio Murciano de Salud, Centro de Salud Mental Cartagena,

Hospital Universitario Santa Lucía, Cartagena, Murcia, Spain

2

Servicio Murciano de Salud, Unidad de Corta Estancia, Hospital

Román Alberca, Murcia, Spain

3

Servicio Murciano de Salud, Residencia Psicogeriátrica Virgen del

Valle, El Palmar, Murcia, Spain

4

Servicio Murciano de Salud, Unidad Regional de Media Estancia,

Hospital Psiquiátrico Román Alberca, Murcia, Spain

5

Servicio Murciano de Salud, Centro de Salud Mental Cartagena,

Hospital Universitario Santa Lucía, Cartagena, Murcia, Spain

6

Servicio Murciano de Salud, Hospital Universitario Santa Lucía,

Cartagena, Murcia, Spain

7

Servicio Murciano de Salud, Centro de Salud Mental Cartagena,

Cartagena, Murcia, Spain